Several experts are making efforts to develop a standardized method for evaluating TILs using hematoxylin and eosin–stained sections and to improve consistency and reproducibility in measuring TILs for future studies [51]; (2) in the analyses of TILs subsets, some studies used combined multiple markers or different kinds of ratios to predict the survival outcome of BC patients, such as CD8/FoxP3 and CD8/CD138 ratios. This evidence concerns the gene SDC1 and breast cancer.